A pharmacogenetics study to predict outcome in patients receiving anti-VEGF therapy in age related macular degeneration
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
PURPOSE: To ascertain whether single nucleotide polymorphisms (SNPs) in the Vascular Endothelial Growth factor (VEGFA), Complement Factor H (CFH), and LOC387715 genes could predict outcome to anti-VEGF therapy for patients with age related macular degeneration (AMD). METHODS: Patients with "wet" AMD were identified by chart review. Baseline optical coherence tomography (OCT) and visual acuity (VA) data, and at least 6 months of clinical follow up after 3 initial monthly injections of bevacizumab or ranibizumab were required for inclusion. Based on OCT and VA, patients were categorized into two possible clinical outcomes: (a) responders and (b) non-responders. DNA was extracted from saliva and genotyped for candidate SNPs in the VEGFA, LOC387715, and CFH genes. Clinical outcomes were statistically compared to patient genotypes. RESULTS: 101 patients were recruited, and one eye from each patient was included in the analysis. 97% of samples were successfully genotyped for all SNPs. We found a statistically significant association between the LOC387715 A69S TT genotype and outcome based on OCT. CONCLUSION: Genetic variation may be associated with outcome in patients receiving anti-VEGF therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration
Martin, D. F., Maguire, M. G., Fine, S. L., Ying, G.-S., Jaffe, G. J., Grunwald, J. E., Toth, C., Redford, M., & Ferris, F. L. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.03.053 · Cited by 1,715
Association of CFH Y402H and LOC387715 A69S with progression of age-related macular degeneration
Seddon, J. M., Francis, P. J., George, S., Schultz, D. W., Rosner, B., & Klein, M. L. (2007) · JAMA · doi:10.1001/jama.297.16.1793 · Cited by 330 · cited 1×
“Each colored diamond represents the –log 10 ( P -value) for that specific SNP. Abbreviations: VEGFA , vascular endothelial growth factor; SNP, single nucleotide polymorphism. of therapy (ie, a prognostic marker) 7,8,13 .”
Lee, A. Y., Raya, A. K., Kymes, S. M., Shiels, A., & Brantley, M. A. (2009) · British Journal of Ophthalmology · doi:10.1136/bjo.2008.150995 · Cited by 134
Cited by
Defining response to anti-VEGF therapies in neovascular AMD
Amoaku, W. M., Chakravarthy, U., Gale, R., Gavin, M., Ghanchi, F., Gibson, J., Harding, S., Johnston, R. L., Kelly, S., Lotery, A., et al. (2015) · Eye · doi:10.1038/eye.2015.48 · Cited by 355
Wu, M., Xiong, H., Xu, Y., Xiong, X., Zou, H., Zheng, M., Wang, X., & Zhou, X. (2017) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2016-309418 · Cited by 36
Chen, G., Tzekov, R., Li, W., Jiang, F., Mao, S., & Tong, Y. (2015) · Scientific Reports · doi:10.1038/srep14517 · Cited by 31
Zhang, J., Liu, Z., Hu, S., & Qi, J. (2021) · Ophthalmic Research · doi:10.1159/000508738 · Cited by 15
“[24] confirmed that A69S was positively correlated with the achievement of dry maculae after three monthly injections of ranibizumab or bevacizumab, suggesting better response of ARMS2 A69S with advanced AMD.”
Background
Metadata
- Authors
- Wood, Kitchens, Kassem, Wood, Stone, Isernhagen, Hancock, Radovich, Waymire, Li, & Schneider, B.
- Venue
- Clinical Ophthalmology
- Publisher
- Informa UK Limited
- Published
- 2013-10
- Volume
- 7
- Pages
- 1987
- ISSN
- 1177-5467 (ISSN-L)
- 1177-5483
- OpenAlex
- W59193101
- Cited by
- 34
- References
- 3
- FWCI
- 3.01
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.